References
- Adler, D. G., Gostout, C. J., Sorbi, D., Burgart, L. J., Wang, L., et al. (2002) Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest. Endosc. 56, 657−662
- Baek, S. J., Wilson, L. C., Hsi, L. C., and Eling, T. E. (2003) Troglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, selectively induces the early growth response-1 gene independently of PPARgamma. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem. 278, 5845− 5853
- Bogazzi, F., Ultimieri, F., Raggi, F., Costa, A., Gasperi, M., et al. (2002) Peroxisome proliferator activated receptor gamma expression is reduced in the colonic mucosa of acromegalic patients. J. Clin. Endocrinol. Metab. 87, 2403−2406
- Brockman, J. A., Gupta, R. A., and Dubois, R. N. (1998) Activation of PPARgamma leads to inhibition of anchorageindependent growth of human colorectal cancer cells. Gastroenterology 115, 1049−1055 https://doi.org/10.1016/S0016-5085(98)70123-4
- Brunmair, B., Gras, F., Neschen, S., Roden, M., Wagner, L., et al. (2001) Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-{gamma}-mediated changes in gene expression. Diabetes 50, 2309−2315
- Burstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., et al. (2003) Use of the peroxisome proliferatoractivated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res. Treat. 79, 391−397
- Bush, C. R., Havens, J. M., Necela, B. M., Su, W., Chen, L., et al. (2007) Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor gamma and calcium signaling in human colorectal cancer cells. J. Biol. Chem. 282, 23387−23401
- Cerbone, A., Toaldo, C., Laurora, S., Briatore, F., Pizzimenti, S., et al. (2007) 4-Hydroxynonenal and PPARgamma ligands affect proliferation, differentiation, and apoptosis in colon cancer cells. Free Radic. Biol. Med. 42, 1661−1670
- Cesario, R. M., Stone, J., Yen, W. C., Bissonnette, R. P., and Lamph, W. W. (2006) Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Lett. 240, 225−233
- Chen, G. G., Lee, J. F., Wang, S. H., Chan, U. P., Ip, P. C., et al. (2002) Apoptosis induced by activation of peroxisomeproliferator activated receptor-gamma is associated with Bcl- 2 and NF-kappaB in human colon cancer. Life Sci. 70, 2631− 2646
- Chen, L., Bush, C. R., Necela, B. M., Su, W., Yanagisawa, M., et al. (2006a) RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells. Mol. Cell. Endocrinol. 251, 17−32
- Chen, L., Necela, B. M., Su, W., Yanagisawa, M., Anastasiadis, P. Z., et al. (2006b) Peroxisome proliferator-activated receptor gamma promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2. Chen, L., Necela, B. M., Su, W., Yanagisawa, M., Anastasiadis, P. Z., et al. (2006b) Peroxisome proliferator-activated receptor gamma promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2. J. Biol. Chem. 281, 24575−24587
- Copland, J. A., Marlow, L. A., Kurakata, S., Fujiwara, K., Wong, A. K., et al. (2006) Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/ CIP1. Oncogene 25, 2304−2317
- Demetri, G. D., Fletcher, C. D., Mueller, E., Sarraf, P., Naujoks, R., et al. (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci USA 96, 3951−3956
- Drori, S., Girnun, G. D., Tou, L., Szwaya, J. D., Mueller, E., et al. (2005) Hic-5 regulates an epithelial program mediated by PPARgamma. Genes Dev. 19, 362−375
- Dubuquoy, L., Rousseaux, C., Thuru, X., Peyrin-Biroulet, L., Romano, O., et al. (2006) PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55, 1341−1349
- Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A. M., et al. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272, 18779−18789
- Fajas, L., Fruchart, J. C., and Auwerx, J. (1998) PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett. 438, 55−60
- Forman, B. M., Chen, J., and Evans, R. M. (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci USA 94, 4312−4317
- Fujiwara, T., Wada, M., Fukuda, K., Fukami, M., Yoshioka, S., et al. (1991) Characterization of CS-045, a new oral antidiabetic agent, II. effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 40, 1213−1218
- Girnun, G. D., Smith, W. M., Drori, S., Sarraf, P., Mueller, E., et al. (2002) APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc. Natl. Acad. Sci USA 99, 13771− 13776
- Gupta, R. A., Sarraf, P., Brockman, J. A., Shappell, S. B., Raftery, L. A., et al. (2003a) Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. J. Biol. Chem. 278, 7431−7438
- Gupta, R. A., Sarraf, P., Mueller, E., Brockman, J. A., Prusakiewicz, J. J., et al. (2003b) Peroxisome proliferatoractivated receptor gamma-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell typespecific mechanisms. J. Biol. Chem. 278, 22669−22677
- Hu, E., Tontonoz, P., and Spiegelman, B. M. (1995) Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha. Proc. Natl. Acad. Sci USA 92, 9856−9860
- Iankova, I., Petersen, R. K., Annicotte, J. S., Chavey, C., Hansen, J. B., et al. (2006) Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Mol. Endocrinol. 20, 1494−1505
- Ikezoe, T., Miller, C. W., Kawano, S., Heaney, A., Williamson, E. A., et al. (2001) Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res. 61, 5307−5310
- Kato, M., Kusumi, T., Tsuchida, S., Tanaka, M., Sasaki, M., et al. (2004) Induction of differentiation and peroxisome proliferator- activated receptor gamma expression in colon cancer cell lines by troglitazone. J. Cancer Res. Clin. Oncol. 130, 73− 79
- Kitamura, S., Miyazaki, Y., Shinomura, Y., Kondo, S., Kanayama, S., et al. (1999) Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn. J. Cancer Res. 90, 75−80
- Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., Hosokawa, M., et al. (2001) Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemicallyinduced aberrant crypt foci in rats. Jpn. J. Cancer Res. 92, 396−403
- Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., Said, J. W., et al. (1998) Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58, 3344−3352
- Kulke, M. H., Demetri, G. D., Sharpless, N. E., Ryan, D. P., Shivdasani, R., et al. (2002) A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 8, 395−399
- Laidler, P., Dulinska, J., and Mrozicki, S. (2007) Does the inhibition of c-myc expression mediate the anti-tumor activity of PPAR's ligands in prostate cancer cell lines? Arch. Biochem. Biophys. 462, 1−12
- Lefebvre, A. M., Chen, I., Desreumaux, P., Najib, J., Fruchart, J. C., et al. (1998) Activation of the peroxisome proliferatoractivated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 4, 1053− 1057
- Lefebvre, M., Paulweber, B., Fajas, L., Woods, J., McCrary, C., et al. (1999) Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J. Endocrinol. 162, 331−340
- Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferatoractivated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953−12956
- Matthiessen, M. W., Pedersen, G., Albrektsen, T., Adamsen, S., Fleckner, J., et al. (2005) Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J. Gastroenterol. 40, 198−205
- McAlpine, C. A., Barak, Y., Matise, I., and Cormier, R. T. (2006) Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int. J. Cancer 119, 2339− 2346
- Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., et al. (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell 1, 465−470
- Mukherjee, R., Jow, L., Croston, G. E., and Paterniti, J. R., Jr. (1997) Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem. 272, 8071−8076
- Niho, N., Takahashi, M., Kitamura, T., Shoji, Y., Itoh, M., et al. (2003a) Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res. 63, 6090−6095
- Niho, N., Takahashi, M., Shoji, Y., Takeuchi, Y., Matsubara, S., et al. (2003b) Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. Cancer Sci. 94, 960−964
- Nissen, S. E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457−2471
- Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., et al. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395, 137−143
- Osawa, E., Nakajima, A., Wada, K., Ishimine, S., Fujisawa, N., et al. (2003) Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124, 361−367
- Saez, E., Tontonoz, P., Nelson, M. C., Alvarez, J. G., Ming, U. T., et al. (1998) Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat. Med. 4, 1058−1061
- Sanchez-Hidalgo, M., Martin, A. R., Villegas, I., and de la Lastra, C. A. (2007) Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Eur. J. Pharmacol. 562, 247−258
- Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., et al. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med. 4, 1046−1052
- Sarraf, P., Mueller, E., Smith, W. M., Wright, H. M., Kum, J. B., et al. (1999) Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol. Cell 3, 799− 804
- Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., et al. (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15, 5336−5348
- Shah, Y. M., Morimura, K., and Gonzalez, F. J. (2007) Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G657−666
- Shimada, T., Kojima, K., Yoshiura, K., Hiraishi, H., and Terano, A. (2002) Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 50, 658−664
- Shirasawa, S., Furuse, M., Yokoyama, N., and Sasazuki, T. (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260, 85−88
- Simoncini, T., Scorticati, C., Mannella, P., Fadiel, A., Giretti, M. S., et al. (2006) Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol. Endocrinol. 20, 1756−71
- Su, W., Bush, C. R., Necela, B., Calcagno, S. R., Murray, N. R., et al. (2007) Differential expression, distribution, and function of PPAR-gamma in the proximal and distal colon. Physiol. Genomics 30, 342−353
- Takayama, T., Katsuki, S., Takahashi, Y., Ohi, M., Nojiri, S., et al. (1998) Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med. 339, 1277−1284
- Tanaka, T., Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., et al. (2001) Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 61, 2424−2428
- Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., and Spiegelman, B. M. (1994a) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8, 1224−1234
- Tontonoz, P., Hu, E., and Spiegelman, B. M. (1994b) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79, 1147−1156
- Tontonoz, P., Hu, E., Devine, J., Beale, E. G., and Spiegelman, B. M. (1995) PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell. Biol. 15, 351−357
- Uppenberg, J., Svensson, C., Jaki, M., Bertilsson, G., Jendeberg, L., et al. (1998) Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J. Biol. Chem. 273, 31108−31112
- Wang, M., Wise, S. C., Leff, T., and Su, T. Z. (1999) Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator- activated receptor-gamma. Diabetes 48, 254−260
- Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., et al. (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 3, 397−403
- Yamakawa-Karakida, N., Sugita, K., Inukai, T., Goi, K., Nakamura, M., et al. (2002) Ligand activation of peroxisome proliferator- activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity. Cell Death Differ. 9, 513−526
- Yamazaki, K., Shimizu, M., Okuno, M., Matsushima-Nishiwaki, R., Kanemura, N., et al. (2007) Synergistic effects of RXR {alpha} and PPAR{gamma} ligands to inhibit growth in human colon cancer cells - phosphorylated RXR{alpha} is a critical target for colon cancer management 1. Gut [Epub ahead of print]
- Yang, K., Fan, K. H., Lamprecht, S. A., Edelmann, W., Kopelovich, L., et al. (2005) Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice. Int. J. Cancer 116, 495−499
- Yokota, T., Sugano, K., Kondo, H., Saito, D., Sugihara, K., et al. (1997) Detection of aberrant crypt foci by magnifying colonoscopy. Gastrointest. Endosc. 46, 61−65
- Yoshizumi, T., Ohta, T., Ninomiya, I., Terada, I., Fushida, S., et al. (2004) Thiazolidinedione, a peroxisome proliferatoractivated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation- promoting effects. Int. J. Oncol. 25, 631−639
- Zhu, X., Lin, Y., Zhang, J., Fu, M., Mao, Z., et al. (2003) Thiazolidinediones, a class of anti-diabetic drugs, inhibit Id2 expression through a PPARgamma-independent pathway in human aortic smooth muscle cells. Cell. Mol. Life Sci. 60, 212−218
- Zhu, Y., Alvares, K., Huang, Q., Rao, M. S., and Reddy, J. K. (1993) Cloning of a new member of the peroxisome proliferator- activated receptor gene family from mouse liver. J. Biol. Chem. 268, 26817−26820